2-ethyl-7-methyl-5H-1,3,4-thiadiazolo<3,2-a>-pyrimidin-5-one | 41837-55-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-ethyl-7-methyl-5H-1,3,4-thiadiazolo<3,2-a>-pyrimidin-5-one
• 英文别名: 2-ethyl-7-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one；2-ethyl-7-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-4-one；2-Aethyl-7-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-4-on；2-ethyl-7-methyl-5H-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one；2-ethyl-7-methyl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one
• CAS: 41837-55-2
• 化学式: C₈H₉N₃OS
• 分子量: 195.245
• InChiKey: ZQJMOEMHLZSDBK-UHFFFAOYSA-N

物化性质

• 熔点：
  110-113 °C
• 沸点：
  296.6±23.0 °C(Predicted)
• 密度：
  1.45±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  70.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-ethyl-7-methyl-5H-1,3,4-thiadiazolo<3,2-a>-pyrimidin-5-one 在 氯 作用下， 以 氯仿 为溶剂， 生成 2-氨基-5-乙基-1,3,4-噻二唑
  参考文献：
  名称：

  Ringspaltungsreaktion von Thiadiazolo- und Triazolopyrimidin-Derivaten

  摘要：

  研究了 7-甲基-5H-1,3,4-噻二唑并[3,2-a]嘧啶-5-酮 (I) 和替代异构体 7-酮 (XI) 的开环和重排反应。 I (R=H) 和 XI (R=H) 用 5% NaOH 处理，通过 N-N 键断裂定量给出甲基硫氧嘧啶 (III)，同时得到 4-甲基-2-硫氰酸基-6(1H)嘧啶酮 (II) )通过用液氨处理。通过用 5% NaOH 处理 I 和 XI（R=烷基），S-C 键断裂，生成相应的酰氨基嘧啶衍生物（IV 和 IV'）和 3-氨基嘧啶硫酮（V 和 V'）。用 5% NaOH 处理 2-肼基衍生物 (I; R=NHNH2) 得到 1-氨基-2-巯基-7-甲基-5H-s-三唑并[1,5-a]嘧啶-5-酮 (VIII ）通过开环和回收。另一方面，I的嘧啶部分（R=Et和i-Pr）在氯的作用下裂解，得到2-氨基-1,3,4-噻二唑（X；R=Et和t-Pr）。

  DOI：

  10.1246/bcsj.47.2813
• 作为产物：
  描述：

  2,7-dimethyl-5H-1,3,4-thiadiazolo<3,2-a>pyrimidin-5-one 、 硫酸 生成 2-ethyl-7-methyl-5H-1,3,4-thiadiazolo<3,2-a>-pyrimidin-5-one
  参考文献：
  名称：

  KORNIS G.; MARKS P. J.; CHIDESTER C. G., J. ORG. CHEM., 1980, 45, NO 24, 4860-4863

  摘要：

  DOI：

文献信息

• Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Services

  公开号：US10869865B2

  公开（公告）日：2020-12-22

  The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R1—R2  (I), wherein Q, Y, R1, and R2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.

  本发明提供了治疗或预防疟疾的方法，包括向动物施用有效量的式 I 化合物： Q-Y-R1-R2 (I)、 其中Q、Y、R1和R2如本文所述。本发明还提供了抑制动物体内寄生虫的质体表面阴离子通道的方法。本发明还提供了药物组合物，其包含式 I 所代表的化合物与式 II、V 和 VI 所代表的任意一种或多种化合物的组合。本发明还提供了药物组合物用于治疗或预防疟疾或抑制包括人类在内的动物的质体表面阴离子通道的用途。本发明还提供了 clag3 氨基酸序列和相关核酸、载体、宿主细胞、细胞群、抗体和药物组合物。
• The Structure of Certain Polyazaindenes. II. The Product from Ethyl Acetoacetate and 3-Amino-1,2,4-triazole
  作者：C. F. H. ALLEN、H. R. BEILFUSS、D. M. BURNESS、G. A. REYNOLDS、J. F. TINKER、J. A. VanALLAN

  DOI：10.1021/jo01088a014

  日期：1959.6
• Reaction of .beta.-oxo esters with 2-amino-1,3,4-thiadiazoles. A reinvestigation
  作者：Gabriel Kornis、Pamela J. Marks、Constance G. Chidester

  DOI：10.1021/jo01312a012

  日期：1980.11
• OKABE T.; TANIGUCHI E.; MAEKAWA K., BULL. CHEM. SOC. JAP. <BCSJ-A8>, 1974, 47, NO 11, 2813-2817
  作者：OKABE T.、 TANIGUCHI E.、 MAEKAWA K.

  DOI：——

  日期：——
• PLASMODIAL SURFACE ANION CHANNEL INHIBITORS FOR THE TREATMENT OR PREVENTION OF MALARIA
  申请人：The United States of America, as represented by the Secretary, Department of Health and Human Serv

  公开号：US20190183889A1

  公开（公告）日：2019-06-20

  The invention provides methods of treating or preventing malaria comprising administering to an animal an effective amount of a compound of formula I: Q-Y—R 1 —R 2 (I), wherein Q, Y, R 1 , and R 2 are as described herein. Methods of inhibiting a plasmodial surface anion channel of a parasite in an animal are also provided. The invention also provides pharmaceutical compositions comprising a compound represented by formula I in combination with any one or more compounds represented by formulas II, V, and VI. Use of the pharmaceutical compositions for treating or preventing malaria or for inhibiting a plasmodial surface anion channel in animals including humans are also provided. Also provided by the invention are clag3 amino acid sequences and related nucleic acids, vectors, host cells, populations of cells, antibodies, and pharmaceutical compositions.